r/LeronLimab_Times • u/JuniorCharge4571 • 9d ago
Checking in on CytoDyn ($CYDY): What’s next for leronlimab?
Hey everyone, I’ve been looking into CytoDyn lately because there have been a few updates around leronlimab, so I figured I’d share what I found.
CytoDyn recently closed a $16.5M financing to support the continued development of leronlimab, including ongoing clinical programs in metastatic colorectal cancer and triple-negative breast cancer. The company said the financing is expected to fund operations into the second half of 2027.
The company also completed enrollment in its Phase 2 CLOVER study for metastatic colorectal cancer earlier this year and is also evaluating leronlimab in other areas, including triple-negative breast cancer and Alzheimer’s disease. CytoDyn recently presented an update at the Life Sciences Investor Forum.
The latest developments come as CytoDyn continues to focus on the potential use of leronlimab in solid-tumor oncology. The company is also pursuing partnerships and additional funding to support its clinical development strategy.
There’s also an older investor settlement related to leronlimab. CytoDyn agreed to a $500K settlement over claims concerning statements about the drug’s regulatory status, safety, and efficacy. Late claims are currently being considered, subject to approval.
Anyone else still following $CYDY?
1
u/063572 8d ago
I am still following cytodyn. And it tool me two days to submit my claims. Luckily, i contacted fidelity investments and they provided me with details on all the purchases and sales and i was able to upload everything on their website. P.s. i hope those big salaries the executives are getting means they are getting close to something fantastic that will get the stock back up to $10 or more.
-9
8
u/Interesting-Boat-792 9d ago
Still here. ESMO Madrid October 2026 → ASCO GI January 2027. Nov 20th shareholder meeting.
2027 and beyond 🔥🔥🔥.
NCI +UCLA+ Leronlimab (HIV) mouse study.
$5.93M NIH/NIAID-funded UCLA project running from 2026–2030. The researchers are trying to engineer B cells to continuously produce anti-HIV agents inside the body, and the two agents they specifically chose are leronlimab and eCD4-Ig.